MX2016015796A - Lanzaderas cerebrales de anticuerpo humanizado anti-tau(ps422) y usos de las mismas. - Google Patents

Lanzaderas cerebrales de anticuerpo humanizado anti-tau(ps422) y usos de las mismas.

Info

Publication number
MX2016015796A
MX2016015796A MX2016015796A MX2016015796A MX2016015796A MX 2016015796 A MX2016015796 A MX 2016015796A MX 2016015796 A MX2016015796 A MX 2016015796A MX 2016015796 A MX2016015796 A MX 2016015796A MX 2016015796 A MX2016015796 A MX 2016015796A
Authority
MX
Mexico
Prior art keywords
tau
humanized anti
antibody
shuttles
antibody brain
Prior art date
Application number
MX2016015796A
Other languages
English (en)
Inventor
Goepfert Ulrich
Bader Martin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015796A publication Critical patent/MX2016015796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se comunica un complejo no covalente de un anticuerpo haptenilado que se une específicamente a Tau (pS422) humana y un anticuerpo biespecífico anti-receptor de barrera hematoencefálica/hapteno.
MX2016015796A 2014-06-26 2015-06-25 Lanzaderas cerebrales de anticuerpo humanizado anti-tau(ps422) y usos de las mismas. MX2016015796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14174042 2014-06-26
PCT/EP2015/064321 WO2015197735A1 (en) 2014-06-26 2015-06-25 HUMANIZED ANTI-Tau(pS422) ANTIBODY BRAIN SHUTTLES AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2016015796A true MX2016015796A (es) 2017-04-25

Family

ID=51063279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015796A MX2016015796A (es) 2014-06-26 2015-06-25 Lanzaderas cerebrales de anticuerpo humanizado anti-tau(ps422) y usos de las mismas.

Country Status (17)

Country Link
US (1) US10251952B2 (es)
EP (1) EP3164152B1 (es)
JP (1) JP6683631B2 (es)
KR (1) KR20170023837A (es)
CN (1) CN106456760B (es)
AR (1) AR100978A1 (es)
AU (1) AU2015279184A1 (es)
BR (1) BR112016022794A2 (es)
CA (1) CA2944834A1 (es)
ES (1) ES2787180T3 (es)
IL (1) IL247900A0 (es)
MX (1) MX2016015796A (es)
PL (1) PL3164152T3 (es)
SG (1) SG11201610741WA (es)
TW (1) TW201625680A (es)
WO (1) WO2015197735A1 (es)
ZA (1) ZA201606557B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
IL307373A (en) 2017-02-17 2023-11-01 Denali Therapeutics Inc Polypeptides that bind to a transgenic transferrin receptor
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20200074A1 (ar) 2017-10-16 2020-04-30 Eisai R&D Man Co Ltd أجسام مضادة ضد tau واستخداماتها
WO2019094576A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Bace-tau bispecific antibodies
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1991006305A1 (en) 1989-11-07 1991-05-16 Bristol-Myers Squibb Company Oligomeric immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH06500780A (ja) 1990-08-31 1994-01-27 ブリストル―マイアーズ　スクイブ　カンパニー ホモ接合免疫グロブリン
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
ATE386115T1 (de) 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20040166115A1 (en) * 2002-11-15 2004-08-26 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DK1250600T3 (da) 2000-01-24 2007-02-05 Innogenetics Nv Diagnosticering af tauopatier ved bestemmelse af tau/phospho-tau-forholdet
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP4948413B2 (ja) 2004-09-23 2012-06-06 ジェネンテック， インコーポレイテッド システイン操作抗体および結合体
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2465872A3 (en) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP5127474B2 (ja) 2008-01-24 2013-01-23 キヤノン株式会社 画像投射装置
US8946165B2 (en) 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN102481367B (zh) 2009-07-06 2015-04-29 弗·哈夫曼-拉罗切有限公司 结合地高辛配基的双特异性抗体
US8778343B2 (en) 2009-08-28 2014-07-15 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
US8936792B2 (en) 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
CN103124743A (zh) 2009-12-29 2013-05-29 新兴产品开发西雅图有限公司 Ron结合构建物及其使用方法
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
DK2625198T3 (en) 2010-10-07 2015-09-28 Ac Immune Sa Antibodies that recognize the phosphorylated tau
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
US20120171120A1 (en) * 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
BR112013014644A2 (pt) 2011-01-03 2017-03-07 F Hoffmann - La Roche Ag composição farmacêutica e complexo
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6541974B2 (ja) 2011-12-20 2019-07-10 メディミューン，エルエルシー 二重特異的抗体足場用改変ポリペプチド
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
AU2013285422B2 (en) 2012-07-04 2017-04-27 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
CN104736185B (zh) * 2012-08-16 2018-03-20 埃匹瑞恩股份有限公司 治疗Tau病变的方法
PT2890712T (pt) * 2012-08-29 2019-06-28 Hoffmann La Roche Transportador para a barreira hematoencefálica
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles

Also Published As

Publication number Publication date
US10251952B2 (en) 2019-04-09
US20170106084A1 (en) 2017-04-20
CA2944834A1 (en) 2015-12-30
KR20170023837A (ko) 2017-03-06
EP3164152B1 (en) 2020-02-19
AR100978A1 (es) 2016-11-16
PL3164152T3 (pl) 2020-06-15
ES2787180T3 (es) 2020-10-15
CN106456760A (zh) 2017-02-22
IL247900A0 (en) 2016-11-30
AU2015279184A1 (en) 2016-10-06
TW201625680A (zh) 2016-07-16
BR112016022794A2 (pt) 2017-10-17
EP3164152A1 (en) 2017-05-10
ZA201606557B (en) 2018-05-30
CN106456760B (zh) 2022-06-10
JP2017520557A (ja) 2017-07-27
WO2015197735A1 (en) 2015-12-30
JP6683631B2 (ja) 2020-04-22
SG11201610741WA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
MX2016015796A (es) Lanzaderas cerebrales de anticuerpo humanizado anti-tau(ps422) y usos de las mismas.
MX2020003512A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
HK1255040A1 (zh) 治療癌症的抗pd-1抗體和雙特異性抗cd20/抗cd3抗體組合
IL260000A (en) Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
IL249315A0 (en) Monoclonal antibodies against her2 epitope and methods of using them
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
GB201517855D0 (en) Humanized anti-ox40 antibodies and uses thereof
HK1255465A1 (zh) 雙特異性抗人cd20/人轉鐵蛋白受體抗體及使用方法
IL286208A (en) Monoclonal antibodies of human origin and methods of using them
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
RS61958B1 (sr) Anti-cd28 humanizovana antitela formulisana za primenu na ljudima
MX2017001686A (es) Anticuerpos anti-ceramida.
NZ733454A (en) Treatment of autoimmune disorders with cd154 antibodies
RS64530B1 (sr) Monoklonalna antitela protiv krevetnih stenica i postupci za njihovo pravljenje i upotrebe
ZA201901042B (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
ZA202002044B (en) Monoclonal antibody to il-5rα
PT3390450T (pt) Anticorpos humanizados anti-cd28 formulados para administração a humanos
GB201403613D0 (en) Broadly neutralizing monoclonal antibodies against HIV-1